- Home
- GTES vs ERAS Comparison
GTES vs ERAS Comparison
Compare GTES & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTES | ERAS |
|---|---|---|
| Founded | 1911 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.3B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GTES | ERAS |
|---|---|---|
| Price | $24.91 | $14.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $33.25 | $24.11 |
| AVG Volume (30 Days) | 1.6M | ★ 4.8M |
| Earning Date | 10-30-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.73 | ★ 36.23 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.93 | N/A |
| Revenue Next Year | $4.99 | N/A |
| P/E Ratio | $29.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.88 | $2.11 |
| 52 Week High | $30.34 | $24.28 |
Technical Indicators
Market Signals| Indicator | GTES | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 42.55 |
| Support Level | $23.66 | $13.56 |
| Resistance Level | $26.97 | $15.03 |
| Average True Range (ATR) | 0.96 | 1.05 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 15.03 | 28.71 |
Price Performance
Historical ComparisonAbout GTES Gates Industrial Corporation plc
Gates Industrial Corp Ltd operates as a manufacturer of application-specific fluid power and power transmission solutions. Its product portfolio includes engineered components used in power transmission and fluid power applications across a range of end markets and geographic regions.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.